







**Lab No.** : ASN/24-06-2023/SR7799906

Patient Name : NI SHA Age : 38 Y 0 M 17 D

Gender : F

Lab Add. : Newtown, Kolkata-700156

Ref Dr. : Dr.MEDICAL OFFICER
Collection Date: 24/Jun/2023 09:58AM

**Report Date** : 25/Jun/2023 11:43AM

Test Name Result Unit Bio Ref. Interval Method

PHOSPHORUS-INORGANIC, BLOOD, GEL SERUM

PHOSPHORUS-INORGANIC, BLOOD

2 9

mg/dL

2.4-5.1 mg/dL

Phosphomolybdate/UV

Dr NEEPA CHOWDHURY MBBS MD (Biochemistry) Consultant Biochemist



Lab No. : SR7799906	Name : NISHA		Age/G: 38 Y 0 M 17 D / F	Date : 24-06-2023
*CALCIUM, BLOOD				
CALCIUM,BLOOD	8.80	mg/dL	8.6 - 10.2 mg/dl	ARSENAZO III
*GLUCOSE, FASTING, BLOO	D, NAF PLASMA			
GLUCOSE,FASTING	85	mg/dL	(70 - 110 mg/dl)	GOD POD
*URINE ROUTINE ALL, ALL	, URINE			
PHYSICAL EXAMINATION	<u>l</u>			
COLOUR	PALE YELLOW			
APPEARANCE	CLEAR			
CHEMICAL EXAMINATION	<u>l</u>			
рН	7.0		4.6 - 8.0	Dipstick (triple indicator method)
SPECIFIC GRAVITY	1.010		1.005 - 1.030	Dipstick (ion concentration method)
PROTEIN	NOT DETECTED		NOT DETECTED	Dipstick (protein error of pH indicators)/Manual
GLUCOSE	NOT DETECTED		NOT DETECTED	Dipstick(glucose-oxidase-peroxidase method)/Manual
KETONES (ACETOACETIC A ACETONE)	CID, NOT DETECTED		NOT DETECTED	Dipstick (Legals test)/Manual
BLOOD	NOT DETECTED		NOT DETECTED	Dipstick (pseudoperoxidase reaction)
BILIRUBIN	NEGATIVE		NEGATIVE	Dipstick (azo-diazo reaction)/Manual
UROBILINOGEN	NEGATIVE		NEGATIVE	Dipstick (diazonium ion reaction)/Manual
NITRITE	NEGATIVE		NEGATIVE	Dipstick (Griess test)
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	Dipstick (ester hydrolysis reaction)
MICROSCOPIC EXAMINAT	<u> TION</u>			
LEUKOCYTES (PUS CELLS)	1-2	/hpf	0-5	Microscopy
EPITHELIAL CELLS	1-2	/hpf	0-5	Microscopy
RED BLOOD CELLS	NOT DETECTED	/hpf	0-2	Microscopy
CAST	NOT DETECTED		NOT DETECTED	Microscopy
CRYSTALS	NOT DETECTED		NOT DETECTED	Microscopy
BACTERIA	NOT DETECTED		NOT DETECTED	Microscopy
YEAST	NOT DETECTED		NOT DETECTED	Microscopy

#### Note:

- 1. All urine samples are checked for adequacy and suitability before examination.
- 2. Analysis by urine analyzer of dipstick is based on reflectance photometry principle. Abnormal results of chemical examinations are confirmed by manual methods.
- 3. The first voided morning clean-catch midstream urine sample is the specimen of choice for chemical and microscopic analysis.
- 4. Negative nitrite test does not exclude urinary tract infections.
- $5.\ Trace\ proteinuria\ can\ be\ seen\ in\ many\ physiological\ conditions\ like\ exercise,\ pregnancy,\ prolonged\ recumbency\ etc.$
- 6. False positive results for glucose, protein, nitrite, urobilinogen, bilirubin can occur due to use of certain drugs, therapeutic dyes, ascorbic acid, cleaning agents used in urine collection container.
- 7. Discrepancy between results of leukocyte esterase and blood obtained by chemical methods with corresponding pus cell and red blood cell count by microscopy can occur due to cell lysis.
- 8. Contamination from perineum and vaginal discharge should be avoided during collection, which may falsely elevate epithelial cell count and show presence of bacteria and/or yeast in the urine.

CREATININE, BLOOD, GEL SERUM	0.65	mg/dL	0.60 - 1.1 mg/dl	ENZYMATIC
*TOTAL PROTEIN [BLOOD] ALB:GLO	RATIO,.			
TOTAL PROTEIN	7.00	g/dL	6.6 - 8.7 g/dL	BIURET METHOD
ALBUMIN	4.3	g/dl	3.5-5.2 g/dl	BCG
GLOBULIN	2.70	g/dl	1.8-3.2 g/dl	Calculated
AG Ratio	1.59		1.0 - 2.5	Calculated

**Lab No.** : ASN/24-06-2023/SR7799906 Page 2 of 10



ab No. : SR7799906 Name : NISH	4		Age/G: 38 Y 0 M 17 D / F	Date : 24-06-2023
*CHLORIDE, BLOOD , .				
CHLORIDE,BLOOD	108	mEq/L	98 - 107 mEq/L	ISE DIRECT
*SODIUM, BLOOD , GEL SERUM				
SODIUM,BLOOD	139	mEq/L	136 - 145 mEq/L	ISE DIRECT
JREA,BLOOD	10.8	mg/dl	12.8-42.8 mg/dl	UREASE-GLDH
ESTIMATED TWICE.				
*CBC WITH PLATELET (THROMBOCYTE)	COUNT , EDTA WH	IOLE BLOOD		
HEMOGLOBIN	11.9	g/dL	12 - 15	PHOTOMETRIC
WBC	4.4	*10^3/µL	4 - 10	DC detection method
RBC	3.80	*10^6/µL	3.8 - 4.8	DC detection method
PLATELET (THROMBOCYTE) COUNT	130	*10^3/µL	150 - 450*10^3/μL	DC detection method/Microscopy
DIFFERENTIAL COUNT				
NEUTROPHILS	57	%	40 - 80 %	Flowcytometry/Microscopy
LYMPHOCYTES	37	%	20 - 40 %	Flowcytometry/Microscopy
MONOCYTES	04	%	2 - 10 %	Flowcytometry/Microscopy
EOSINOPHILS	02	%	1 - 6 %	Flowcytometry/Microscopy
BASOPHILS	00	%	0-0.9%	Flowcytometry/Microscopy
CBC SUBGROUP				
HEMATOCRIT / PCV	35.4	%	36 - 46 %	Calculated
MCV	93.1	fl	83 - 101 fl	Calculated
MCH	31.4	pg	27 - 32 pg	Calculated
MCHC	33.7	gm/dl	31.5-34.5 gm/dl	Calculated
RDW - RED CELL DISTRIBUTION WIDTH	13.3	%	11.6-14%	Calculated
PDW-PLATELET DISTRIBUTION WIDTH	36.7	fL	8.3 - 25 fL	Calculated
MPV-MEAN PLATELET VOLUME	15.5		7.5 - 11.5 fl	Calculated
*ESR (ERYTHROCYTE SEDIMENTATION	<b>RATE)</b> , EDTA WHO	DLE BLOOD		
1stHour	22	mm/hr	0.00 - 20.00 mm/hr	Westergren
*URIC ACID, BLOOD , GEL SERUM				
URIC ACID,BLOOD	4.50	mg/dl	2.4 - 5.7 mg/dl	URICASE
PDF Attached				
*GLYCATED HAEMOGLOBIN (HBA1C), E	DTA WHOLE BLOO	D		
GLYCATED HEMOGLOBIN (HBA1C)	4.5	%	***FOR BIOLOGICAL REFERENCE INTERVAL DETAILS , PLEASE REFER TO THE BELOW MENTIONED REMARKS/NOTE WITH ADDITIONAL CLINICAL INFORMATION ***	
HbA1c (IFCC)	26.0	mmol/mol		HPLC

Clinical Information and Laboratory clinical interpretation on Biological Reference Interval:

Analyzer used: BIORAD D-10

**Lab No.** : ASN/24-06-2023/SR7799906 Page 3 of 10



Lab No. : SR7799906 Name : NISHA Age/G : 38 Y 0 M 17 D / F Date : 24-06-2023

Method: HPLC

#### Recommendations for glycemic targets

Ø Patients should use self-monitoring of blood glucose (SMBG) and HbA1c levels to assess glycemic control.

Ø The timing and frequency of SMBG should be tailored based on patients' individual treatment, needs, and goals.

Ø Patients should undergo HbA1c testing at least twice a year if they are meeting treatment goals and have stable glycemic control.

 $\emptyset$  If a patient changes treatment plans or does not meet his or her glycemic goals, HbA1c testing should be done quarterly.

 $\emptyset$  For most adults who are not pregnant, HbA1c levels should be <7% to help reduce microvascular complications and macrovascular disease . Action suggested >8% as it indicates poor control.

Ø Some patients may benefit from HbA1c goals that are stringent.

Result alterations in the estimation has been established in many circumstances, such as after acute/ chronic blood loss, for example, after surgery, blood transfusions, hemolytic anemia, or high erythrocyte turnover; vitamin  $B_{12}$ / folate deficiency, presence of chronic renal or liver disease; after administration of high-dose vitamin E / C; or erythropoietin treatment.

Reference: Glycated hemoglobin monitoring BMJ 2006; 333;586-8

#### References:

\*LIPID PROFILE, GEL SERUM

1. Chamberlain JJ, Rhinehart AS, Shaefer CF, et al. Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med. Published online 1 March 2016. doi:10.7326/M15-3016.

CHOLESTEROL-TOTAL	141	mg/dL	Desirable: < 200 mg/dL Borderline high: 200-239 High: > or =240 mg/dL	CHOD PAP Method
TRIGLYCERIDES	121	mg/dL	NORMAL < 150 BORDERLINE HIGH 150-199 HIGH 200-499 VERY HIGH > 500	GPO-PAP
HDL CHOLESTEROL	38	mg/dL	42-88 mg/dl	DIRECT METHOD
LDL CHOLESTEROL DIRECT	79	mg/dL	OPTIMAL: <100 mg/dL, Near optimal/ above optimal: 100-129 mg/dL, Borderline high: 130-159 mg/dL, High: 160-189 mg/dL, Very high: >=190 mg/dL	
VLDL	24	mg/dL	< 40 mg/dl	Calculated
CHOL HDL Ratio	3.7		LOW RISK 3.3-4.4 AVERAGE RISK 4.47-7.1 MODERATE RISK 7.1-11.0 HIGH RISK >11.0	Calculated
*POTASSIUM, BLOOD , GEL SERUM				
POTASSIUM,BLOOD	4.30	mEq/L	3.1-5.5 mEq/L	ISE DIRECT
*THYROID PANEL (T3, T4, TSH), GEL S	ERUM			
T3-TOTAL (TRI IODOTHYRONINE)	0.90	ng/ml	0.9 - 2.2 ng/ml	CLIA
T4-TOTAL (THYROXINE)	7.4	5.5-16 microgram/dl	5.5-16 microgram/dl	CLIA

# BIOLOGICAL REFERENCE INTERVAL: [ONLY FOR PREGNANT MOTHERS]

Trimester specific TSH LEVELS during pregnancy:

TSH (THYROID STIMULATING HORMONE) 4.20

FIRST TRIMESTER : 0.10 2.50  $\mu$  IU/mL SECOND TRIMESTER : 0.20 3.00  $\mu$  IU/mL THIRD TRIMESTER : 0.30 3.00  $\mu$  IU/mL

References:

**Lab No.** : ASN/24-06-2023/SR7799906 Page 4 of 10

0.5-4.7 uIU/ml

CLIA

uTU/mI

<sup>2.</sup> Mosca A, Goodall I, Hoshino T, Jeppsson JO, John WG, Little RR, Miedema K, Myers GL, Reinauer H, Sacks DB, Weykamp CW. International Federation of Clinical Chemistry and Laboratory Medicine, IFCC Scientific Division. Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group. Clin Chem Lab Med. 2007;45(8):1077-1080.



Lab No. : SR7799906 Name : NISHA Age/G : 38 Y 0 M 17 D / F Date : 24-06-2023

1. Indian Thyroid Society guidelines for management of thyroid dysfunction during pregnancy. Clinical Practice Guidelines, New Delhi: Elsevier; 2012.

- 2. Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, et al. Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum. Thyroid 2011; 21:1081-25.
- 3. Dave A, Maru L, Tripathi M. Importance of Universal screening for thyroid disorders in first trimester of pregnancy. Indian J Endocr Metab [serial online] 2014 [cited 2014 Sep 25]; 18: 735-8. Available from: http://www.ijem.in/text.asp? 2014/18/5/735/139221.

Dr Sayak Biswas MBBS, MD

Consultant Pathologist









Lab No.: SR7799906 Name: NISHA Age/G: 38 Y 0 M 17 D / F Date: 25-06-2023

BLOOD GROUP ABO+RH [GEL METHOD], EDTA WHOLE BLOOD

ABO Gel Card

POSITIVE Gel Card RH

**TECHNOLOGY USED: GEL METHOD** 

ADVANTAGES:

Gel card allows simultaneous forward and reverse grouping.

Card is scanned and record is preserved for future reference.

Allows identification of Bombay blood group.

Daily quality controls are run allowing accurate monitoring.

Historical records check not performed.

Bidisha Champholy

Dr. Bidisha Chakraborty Consultant Pathologist MD, DNB (Pathology) Dip RC Path(UK)

Page 6 of 10 Lab No. ASN/24-06-2023/SR7799906



Lab No. : ASN/24-06-2023/SR7799906 Lab Add. : ASANSOL

Ref Dr. Patient Name : NISHA : Dr.MEDICAL OFFICER

: 38 Y 0 M 17 D **Collection Date:** Age

Gender : F **Report Date** : 24/Jun/2023 02:55PM



# **DEPARTMENT OF CARDIOLOGY REPORT OF E.C.G.**

# **DATA**

HEART RATE	:	<b>72</b> bpm
PR INTERVAL	:	137 ms
QRS DURATION	:	68 ms
QT INTERVAL	:	358 ms
QTC INTERVAL	:	392 ms

# **AXIS**

P WAVE	:	64 degree
QRS WAVE	:	30 degree
T WAVE	:	18 degree

**IMPRESSION**: Normal sinus rhythm, within normal limit.

\*\*\* Please correlate clinically \*\*\*

Dr. A C RAY

Department of Non-invasive Cardiology

Page 7 of 10

**Lab No.** : ASN/24-06-2023/SR7799906



Patient Name : NISHA Ref Dr. : Dr.MEDICAL OFFICER

Age :  $38 \ Y \ 0 \ M \ 17 \ D$  Collection Date:

**Gender** : F **Report Date** : 24/Jun/2023 11:40AM



# X-RAY REPORT OF CHEST (PA)

# **FINDINGS:**

No active lung parenchymal lesion is seen.

Both the hila are normal in size, density and position.

Mediastinum is in central position. Trachea is in midline.

Domes of diaphragm are smoothly outlined. Position is within normal limits.

Lateral costo-phrenic angles are clear.

The cardio-thoracic ratio is normal.

Bony thorax reveals no definite abnormality.

## **IMPRESSION:**

• Normal study.

DR. PRASHANT. Y. JOSHI MD, Radiologist

**Lab No.** : ASN/24-06-2023/SR7799906



Patient Name : NISHA Ref Dr. : Dr.MEDICAL OFFICER

Age :  $38 \ Y \ 0 \ M \ 17 \ D$  Collection Date:

**Gender** : F **Report Date** : 24/Jun/2023 05:14PM



### ULTRASONOGRAPHY OF WHOLE ABDOMEN

<u>LIVER</u>: Normal in shape, size (11.5 cm) and **shows increased echogenicity.** No focal lesion is seen. Intrahepatic biliary radicles are not dilated. The portal vein branches and hepatic veins are normal.

**GALL BLADDER**: Well distended lumen shows no intra-luminal calculus or mass. Wall thickness is normal. No pericholecystic collection or mass formation is noted.

**PORTA HEPATIS:** The portal vein is normal in caliber (0.87 cm) with clear lumen. The common bile duct is normal in caliber. Visualized lumen is clear. Common bile duct measures 0.46 cm in diameter.

**PANCREAS**: It is normal in shape, size and echopattern. Main pancreatic duct is not dilated. No focal lesion is seen. The peripancreatic region shows no abnormal fluid collection.

**SPLEEN:** It is normal in shape, size (8.7 cm) and shows homogeneous echopattern. No focal lesion is seen. No abnormal venous dilatation is seen in the splenic hilum.

<u>KIDNEYS</u>: Both Kidneys are normal in shape, size and position. Cortical echogenicity and thickness are normal with normal cortico-medullary differentiation in both kidneys. No calculus, hydronephrosis or mass is noted. The perinephric region shows no abnormal fluid collection.

**RIGHT KIDNEY** measures 9.3 cm **LEFT KIDNEY** measures 8.4 cm

**URINARY BLADDER:** It is adequately distended providing optimum scanning window. The lumen is clear and wall thickness is normal. Post void study shows no residual urine volume.

<u>UTERUS</u>: It is normal in shape, size (8.2 x 5.1 x 4.9 cm) and echopattern. No focal myometrial lesion is seen. Endometrial echo is in midline. Double layer of endometrial echo measures 0.46 cm. Endometrial cavity is empty. Cervix is normal (3.5 x 3.3 cm).

**RIGHT OVARY** is normal in shape, size and echopattern. Right ovary measures : 2.7 x 2.6 cm.

**LEFT OVARY** is normal in shape, size and echopattern. Left ovary measures: 2.4 x 2.4 cm.

**POD**: No fluid is seen.

#### **IMPRESSION:**

\* Grade-I hepatic steatosis.

#### Kindly note

 $\hbox{\it \oeta} \ \ Ultrasound \ is \ not \ the \ modality \ of \ choice \ to \ rule \ out \ subtle \ bowel \ lesion. }$ 

Ø Please Intimate us for any typing mistakes and send the report for correction within 7 days.

Ø The science of Radiological diagnosis is based on the interpretation of various shadows produced by both the normal and abnormal tissues and are not always conclusive. Further biochemical and radiological investigation & clinical correlation is required to enable the clinician to reach the final diagnosis.

The report and films are not valid for medico-legal purpose.

Patient Identity not verified.

**Lab No.** : ASN/24-06-2023/SR7799906 Page 9 of 10



**Lab No.** : ASN/24-06-2023/SR7799906

Patient Name : NISHA

**Age** : 38 Y 0 M 17 D

Gender : F

**Lab Add**. : ASANSOL

**Ref Dr.** : Dr.MEDICAL OFFICER

**Collection Date:** 

**Report Date** : 24/Jun/2023 05:14PM



DR. PRASHANT. Y. JOSHI MD, Radiologist

**Lab No.** : ASN/24-06-2023/SR7799906